Phase 3 OCEAN study results demonstrate melflufen is at least as efficacious as pomalidomide in relapsed refractory multiple myeloma

RCT (n=495) found melflufen was non-inferior to pomalidomide on the primary endpoint of progression free survival (HR 0.817; 95% CI: 0.659-1.012, p=0.064). Based on these data, the company intends to submit a supplementary new drug application to the FDA in quarter 4 of 2021.

Biospace Inc.